JERUSALEM — A drug under investigation by Teva Pharmaceutical Industries and Active Biotech reduced symptoms and progression of disease in patients with multiple sclerosis, according to results of a late-stage clinical trial.
Teva and Active announced the publication of results of the phase-3 "Allegro" study of oral laquinimod in the March 15 issue of the New England Journal of Medicine. The study was conducted in 24 countries and enrolled 1,106 patients with MS who received 0.6 mg of laquinimod per day or placebo.
Data from the study showed that the drug, taken once per day, reduced inflammatory disease, slowed disability progression and decreased loss of brain tissue, but was overall safe for patients with MS.
"The publication of the Allegro results in a prestigious peer-reviewed journal is an important landmark as we continue to research and develop laquinimod," stated Teva Global Branded Products SVP research and development Lesley Russell. "We look forward to continuing to work with regulatory authorities in both the E.U. and the U.S. to bring this novel therapy to the MS community."